DiamiR Brings Blood-Based Alzheimer's Biomarker Tests to AAIC 2026
DiamiR Biosciences presents three studies on blood biomarkers and APOE genotyping for early Alzheimer's detection at London's AAIC.
Summary
DiamiR Biosciences is presenting three research posters at the 2026 Alzheimer's Association International Conference in London. The studies focus on blood-based tools for detecting Alzheimer's risk earlier and more conveniently. One study examines circulating microRNAs in blood that may signal the transition from mild cognitive impairment to Alzheimer's disease. Two others detail methods for genotyping the APOE gene — a major Alzheimer's risk factor — directly from blood or cheek swabs without needing to isolate DNA first, potentially enabling point-of-care testing. These advances could make Alzheimer's risk screening faster, cheaper, and more accessible. DiamiR operates a certified clinical lab and is merging with Aptorum Group to form Niki BioSolutions, pending final closing conditions.
Detailed Summary
Alzheimer's disease remains one of the most devastating conditions affecting older adults, and early detection is widely considered the key to slowing its progression. DiamiR Biosciences, a biomarker diagnostics company, is presenting three research posters at the 2026 Alzheimer's Association International Conference in London this week, highlighting blood-based tools that could transform how clinicians identify Alzheimer's risk before symptoms become severe.
The first major area of research involves circulating microRNAs — tiny regulatory molecules found in blood that reflect activity in the brain. DiamiR's study examines whether specific brain-enriched and inflammatory microRNAs can serve as reliable blood biomarkers marking the progression from mild cognitive impairment to full Alzheimer's disease. If validated, this could allow clinicians to monitor disease trajectory with a simple blood draw rather than costly brain imaging or invasive spinal fluid tests.
The second focus is APOE genotyping. The APOE gene, particularly the E4 variant, is the strongest known genetic risk factor for late-onset Alzheimer's. DiamiR presents two complementary studies: one detailing development of a robust plasma-based APOE genotyping protocol, and another demonstrating automated APOE genotyping directly from blood or buccal (cheek) swabs without DNA isolation — a streamlined, point-of-care ready approach that could bring genetic risk screening into primary care settings.
For health-conscious adults and clinicians focused on longevity, these tools represent a meaningful step toward earlier intervention. Knowing one's APOE status and monitoring cognitive biomarkers over time could inform lifestyle decisions, clinical trials eligibility, and preventive treatment strategies.
Important caveats apply. The presentations are conference posters, not peer-reviewed publications, so findings have not yet undergone full independent scrutiny. Additionally, the pending merger between DiamiR and Aptorum Group introduces organizational uncertainty. Validation in larger, diverse populations will be essential before these tests reach widespread clinical use.
Key Findings
- Blood-based microRNA signatures may reliably track progression from mild cognitive impairment to Alzheimer's disease.
- APOE genotyping directly from blood or cheek swabs without DNA isolation could enable point-of-care Alzheimer's risk testing.
- Plasma-based APOE genotyping protocol optimized for robustness, potentially improving clinical accessibility and accuracy.
- DiamiR's CLIA-certified lab lends credibility to the analytical quality of these biomarker methods.
- DiamiR and Aptorum Group merger, pending final close, will form Niki BioSolutions, consolidating these diagnostics under one entity.
Methodology
This is a corporate press release summarized as a news report by Longevity.Technology. Evidence basis is conference poster presentations, not yet peer-reviewed publications. Source credibility is moderate; DiamiR operates a CLIA-certified, CAP-accredited laboratory, which supports analytical rigor.
Study Limitations
Findings are conference posters and have not been peer-reviewed or published in full; independent validation is pending. Population diversity and sample sizes for these studies are not disclosed in the press release. The corporate merger context introduces potential conflicts of interest that may affect how results are communicated publicly.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: